全球患者来源异种移植模型市场规模（按癌症类型、组织来源、应用、地区、范围和预测）

病患来源异种移植 (PDX) 模型市场规模及预测

2024 年，患者来源的异种移植 (PDX) 模型市场规模价值为 2.5896 亿美元，预计 2024 年至 2031 年期间的复合年增长率为 16.60%，到 2031 年将达到 7.9482 亿美元。 10万美元。患者来源异种移植 (PDX) 模型是癌症研究和治疗开发中复杂且非常有用的工具。该模型涉及将人类肿瘤组织直接植入免疫缺陷小鼠体内。与标准细胞系模型相比，PDX 模型保留了原始人类肿瘤的组织学和遗传特征，使其能够更真实地复製患者体内的肿瘤行为。

PDX 模型在癌症研究中变得越来越重要，因为它们比传统细胞系模型更能准确地描述实际恶性肿瘤。 PDX 模型最常见的用途之一是临床前药物开发和测试。透过将人类肿瘤组织直接移植到免疫缺陷小鼠体内，研究人员能够保留患者肿瘤的组织学特征、遗传多样性和异质性。

未来在癌症研究和个人化治疗中使用患者来源异种移植 (PDX) 模型有可能改变对许多恶性肿瘤的理解和治疗。 PDX 模型是将人类肿瘤组织移植到免疫缺陷小鼠体内，由于其能够准确模拟人类肿瘤的复杂性和异质性，因此变得越来越有价值。

病患来源异种移植 (PDX) 模型的全球市场动态

影响全球病患来源异种移植 (PDX) 模型市场的关键市场动态

主要市场驱动因子

个人化治疗需求日益增加

PDX 模型最重要的市场推动因素之一是向个人化治疗的转变。精准医疗寻求根据遗传、生活方式和环境为个别患者提供个人化的治疗方案。 PDX 模型涉及将人类肿瘤组织移植到免疫缺陷小鼠体内，忠实模拟人类癌症的生物学特征，包括遗传多样性、异质性和微环境。

癌症研究的进展：

癌症研究的重大进展也推动了 PDX 模型产业的扩张。传统的癌症模型，例如细胞系和基因工程小鼠，通常无法重现复杂的人类恶性肿瘤，因此在药物开发中会出现很高的流失率。然而，PDX 模型提供了更准确的人类癌症生物学影像，并在临床前研究中带来更好的预后结果。

癌症发生率上升

全球癌症发生率的上升是 PDX 模型产业发展的另一个主要驱动力。根据世界卫生组织 (WHO) 的数据，癌症是全球主要死亡原因之一，预计 2020 年将导致约 1,000 万人死亡。癌症发生率的上升推动了对更有效和客製化治疗方案的需求，从而增加了对 PDX 模型的需求。

主要问题

可变性和可重复性

PDX 模型的主要问题之一是其固有的多变性和缺乏可重复性。许多因素会影响 PDX 模型的有效性，包括肿瘤的起源、植入方法和患者肿瘤的生物学。这些参数的变化会促使肿瘤发展模式和治疗结果的显着变化。

免疫系统的差异

在研究与免疫细胞相互作用的人类癌症时，在 PDX 模型中使用免疫缺陷小鼠会带来很大的缺点，因为宿主的免疫系统会被消除。这些动物缺乏免疫系统，因此无法代表对肿瘤生长和药物反应至关重要的免疫环境。

道德和后勤问题：创建和维护 PDX 模型带来了一些道德和实际课题。创建 PDX 模型需要从患者身上获取肿瘤样本，这涉及侵入性手术，这对患者来说是一种负担，并且会引发有关同意和处理人体组织的伦理问题。

主要趋势：

增强个人化医疗客製化

PDX 模型最显着的趋势之一是其在个人化医疗中的应用日益广泛。研究人员使用 PDX 模型来产生特定于患者的肿瘤模型，以便更好地预测个体对治疗的反应。这种客製化需要将患者的肿瘤组织移植到免疫缺陷小鼠体内，使其发育并模仿原始肿瘤的异质性。

与基因组和组学资料的整合：

PDX 模型与基因组和组学资料的整合是另一个重要趋势。高通量定序和分子分析技术的进步使研究人员能够更深入地瞭解肿瘤的遗传和分子特征。 PDX 模型越来越多地用于验证这些结果并探索基因改变和分子路径如何影响药物反应。

扩展到新的癌症类型和药物联合疗法

目前明显的趋势是将 PDX 模型的使用范围扩大到新型肿瘤类型和药物组合。 PDX 模型先前用于治疗乳癌和肺癌等特征明确的疾病，现在用于治疗更罕见、更具课题性的癌症，包括胰臟癌和脑癌。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第三章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章。

• 乳癌
• 肺癌
• 大肠癌
• 摄护腺癌

第 5 章。

• 实体肿瘤
• 血液系统恶性肿瘤

第 6 章 患者来源的异种移植 (PDX) 模型市场（按应用）

• 临床前药物开发
• 生物标记分析
• 精准医疗
• 毒性测试

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第十章 公司简介

• Crown Bioscience Inc
• WuXi AppTec
• Champions Oncology
• The Jackson Laboratory
• Charles River Laboratories International Inc
• Taconic Biosciences Inc
• Oncodesign Precision Medicine
• Inotiv Inc
• EPO Berlin-Buch GmbH
• Xentech

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Patient Derived Xenograft (PDX) Models Market Size and Forecast

Patient Derived Xenograft (PDX) Models Market size was valued at USD 258.96 Million in 2024 and is projected to reach USD 794.82 Million by 2031, growing at a CAGR of 16.60% from 2024 to 2031. Patient-Derived Xenograft (PDX) models are a sophisticated and extremely useful tool in cancer research and therapeutic development. These models include transplanting human tumor tissue directly into immunocompromised mice. Compared to standard cell line models, PDX models preserve the histological architecture and genetic properties of the original human tumor making them highly realistic of the tumor's activity in the patient.

They are becoming increasingly important in cancer research as they provide a more accurate portrayal of actual malignancies than traditional cell line models. One of the most common applications for PDX models is preclinical drug development and testing. Researchers can preserve the patient's tumor's histological traits, genetic variety, and heterogeneity by directly implanting human tumor tissues into immunodeficient mice.

The future use of patient-derived xenograft (PDX) models in cancer research and personalized therapy has the potential to transform our understanding and treatment of many malignancies. PDX models which entail implanting human tumor tissues into immunodeficient mice are becoming increasingly valuable due to their ability to accurately imitate the complexity and heterogeneity of human tumors.

Global Patient Derived Xenograft (PDX) Models Market Dynamics

The key market dynamics that are shaping the global patient derived xenograft (PDX) Models market include:

Key Market Drivers:

Rising Demand for Personalized Treatment:

One of the most important market drivers for PDX models is the shift to personalized treatment. Personalized medicine seeks to personalize treatment solutions to individual patients based on their genetics, lifestyle, and environment. PDX models which entail implanting human tumor tissues into immunodeficient mice, closely mimic the biological properties of human cancers, such as genetic variety, heterogeneity, and the microenvironment.

Advancements in Cancer Research:

Significant advances in cancer research are also driving the expansion of the PDX models industry. Traditional cancer models such as cell lines and genetically engineered mice models, frequently fail to replicate the complexities of human malignancies resulting in high attrition rates in drug development. However, PDX models provide a more accurate picture of human cancer biology resulting in higher prognostic outcomes in preclinical studies.

Increasing Cancer Prevalence

: The global growth in cancer incidence is another major driver of the PDX models industry. According to the World Health Organization (WHO), cancer is one of the main causes of mortality globally accounting for nearly 10 million deaths in 2020. The rising incidence of cancer is driving the need for more effective and customized treatment options which is growing demand for PDX models.

Key Challenges:

Variability and Reproducibility

: One of the key concerns with PDX models is their inherent variability and lack of reproducibility. Numerous factors can influence the effectiveness of a PDX model including the origin of the tumor, the manner of implantation, and the biological properties of the patient's tumor. Variations in these parameters can cause major changes in tumor development patterns and treatment responses.

Immune System Differences

: Using immunodeficient mice in PDX models eliminates the host immune system which is a major disadvantage when investigating human cancers that interact with immune cells. Because these animals lack an immune system, they do not represent the immunological milieu which is critical for tumor growth and medication response.

Ethical and Logistical Concerns: The creation and maintenance of PDX models raises several ethical and practical issues. Creating PDX models necessitates the collecting of tumor samples from patients which includes invasive procedures that can be burdensome for patients and raise ethical concerns about consent and the handling of human tissues.

Key Trends:

Enhanced Customization for Personalized Medicine:

One of the most notable trends in PDX models is their growing usage in personalized medicine. Researchers are using PDX models to create patient-specific tumor models that can better predict individual responses to treatment. This customization entails implanting patient tumor tissues into immunodeficient mice which develop and mimic the original tumor's heterogeneity.

Integration with Genomic and Omics Data:

Integrating PDX models with genomic and omics data is another critical trend. Advances in high-throughput sequencing and molecular profiling have allowed researchers to get a better understanding of tumor genetics and molecular features. PDX models are increasingly being utilized to validate these results and investigate how genetic variants and molecular pathways influence medication responsiveness.

Expansion into Novel Cancer Types and Medication Combinations

: There is a noticeable trend of extending the use of PDX models to novel cancer types and medication combinations. PDX models which were previously utilized for well-characterized diseases like breast and lung cancer are now being used to treat rarer and more difficult cancers including pancreatic and brain tumors.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Patient Derived Xenograft (PDX) Models Market Regional Analysis

Here is a more detailed regional analysis of the global patient derived xenograft (PDX) Models market:

North America:

In North America, the patient-derived xenograft (PDX) models market is dominant driven by increased oncology research and development activities as well as a growing emphasis on customized therapy. The region's global market leadership is supported by its advanced healthcare infrastructure, significant investment in research, and high cancer prevalence all of which drive demand for PDX models. The increasing expenditure on oncology research and development in North America is a major driver of the PDX model industry. According to the National Cancer Institute (NCI), the United States will invest nearly USD 7.5 Billion in cancer research in 2023 representing a significant increase over previous years.

Another significant factor is the growing emphasis on individualized medicine which is strongly aligned with the capabilities of PDX models. Personalized medicine seeks to personalize therapies to individual patients based on genetic, environmental, and lifestyle characteristics. PDX models are useful in this field because they allow researchers to investigate patient-specific cancers and test targeted medicines. The United States Food and Drug Administration (FDA) recognizes the importance of customized medicine, and in 2023, it approved a record number of personalized medicines reflecting the increased demand for models that can simulate unique patient reactions.

Asia Pacific:

The Patient Derived Xenograft (PDX) models market in Asia Pacific is expanding rapidly owing mostly to rising cancer incidence and the need for personalized therapy. China and Japan are the region's fastest-growing markets, due to massive investments in healthcare infrastructure and research. The increased incidence of cancer is a primary driver of the PDX models market in Asia Pacific. According to the World Health Organization (WHO), cancer is still the biggest cause of death in the region. In 2020, there are an anticipated 9.5 million new cancer cases and 5.4 million cancer deaths in Asia.

Another key factor is the increased emphasis on customized medicine which is rapidly gaining popularity in Asia Pacific. Personalized medicine seeks to customize treatments to individual genetic profiles, and PDX models play an important part in this effort by offering more realistic preclinical testing environments. The Japanese Ministry of Health, Labour, and Welfare announced that the government is heavily investing in customized medicine and genomics research with significant funds given to precision oncology efforts. This emphasis on individualized treatments drives up the need for PDX models which are critical for testing and validating innovative therapeutic approaches suited to individual patient's needs.

Global Patient Derived Xenograft (PDX) Models Market: Segmentation Analysis

The Global Patient Derived Xenograft (PDX) Models Market is segmented based on Type of Cancer, Source of Tissue, Application, and Geography.

Patient Derived Xenograft (PDX) Models Market, By Type of Cancer

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

Based on the Type of Cancer, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Breast Cancer, Lung Cancer, Colorectal Cancer, and Prostate Cancer. In the global patient derived xenograft (PDX) Models Market, breast cancer models are the dominant segment. This dominance is primarily due to the high incidence of breast cancer globally and its complex biology which necessitates extensive research for effective treatments. PDX models for breast cancer are crucial for understanding tumor heterogeneity, drug resistance, and developing personalized therapies.

Patient Derived Xenograft (PDX) Models Market, By Source of Tissue

• Solid Tumors
• Hematological Malignancies

Based on the Source of Tissue, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Solid Tumors, and Hematological Malignancies. In the patient derived xenograft (PDX) models market, solid tumors are the dominant segment. This dominance is due to the high prevalence of solid tumors compared to hematological malignancies and the extensive research and development focus on these models. The demand for PDX models of solid tumors is driven by their relevance in drug discovery, personalized medicine, and cancer research.

Patient Derived Xenograft (PDX) Models Market, By Application

• Preclinical Drug Development
• Biomarker Analysis
• Precision Medicine

Based on the Application, the Global Patient Derived Xenograft (PDX) Models Market is bifurcated into Preclinical Drug Development, Biomarker Analysis, and Precision Medicine. In the global patient derived xenograft (PDX) models market, preclinical drug development is the dominant application. This dominance stems from the critical role PDX models play in evaluating the efficacy and safety of new drug candidates before clinical trials. PDX models which involve implanting human tumors into immunocompromised mice, provide a more accurate representation of human cancer compared to traditional cell lines.

Patient Derived Xenograft (PDX) Models Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World

Based on Geography, the Global Patient Derived Xenograft (PDX) Models Market is classified into North America, Europe, Asia Pacific, and the Rest of the World. In the patient derived xenograft (PDX) models market, North America holds the dominant position. This leadership is primarily due to advanced healthcare infrastructure, significant investment in research and development, and a high prevalence of cancer which drives demand for innovative cancer research models. The region's strong presence of leading pharmaceutical and biotechnology companies further supports this dominance by facilitating extensive research and clinical trials.

Key Players

• The "Global Patient Derived Xenograft (PDX) Models Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Crown Bioscience, Inc., WuXi AppTec, Champions Oncology, The Jackson Laboratory, Charles River Laboratories International, Inc., Taconic Biosciences, Inc., Oncodesign Precision Medicine, Inotiv, Inc., EPO Berlin-Buch GmbH, Xentech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Global Patient Derived Xenograft (PDX) Models Market Key Developments

• In July 2022, GemPharmatech (GemPharmatech Co., Ltd.) announced that it has signed a strategic license deal with Charles River Laboratories, Inc. for the exclusive sale of their next-generation NOD CRISPR Prkdc Il2r gamma (NCG) mice lines in North America. Charles River will create foundation colonies, with commercially available versions starting in 2023.
• In April 2022, Professor Kamimura's research group at Niigata University developed a novel pancreatic cancer model in wild-type rats using the pancreas-targeted selective hydrodynamic gene delivery approach.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Patient Derived Xenograft (PDX) Models Market, By Type of Cancer

• Breast Cancer
• Lung Cancer
• Colorectal Cancer
• Prostate Cancer

5. Patient Derived Xenograft (PDX) Models Market, By Source of Tissue

• Solid Tumors
• Hematological Malignancies

6. Patient Derived Xenograft (PDX) Models Market, By Application

• Preclinical Drug Development
• Biomarker Analysis
• Precision Medicine
• Toxicology Testing

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Crown Bioscience Inc
• WuXi AppTec
• Champions Oncology
• The Jackson Laboratory
• Charles River Laboratories International Inc
• Taconic Biosciences Inc
• Oncodesign Precision Medicine
• Inotiv Inc
• EPO Berlin-Buch GmbH
• Xentech

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References